[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @ArndtVogel Arndt Vogel Arndt Vogel posts on X about ctx, matterhorn, coffin the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1211086357/interactions)  - X Week XXXXXX +1,821% - X Month XXXXXX +280% - X Months XXXXXXX -XX% - X Year XXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::1211086357/posts_active)  - X Year XX -XXXX% ### Followers: XXXXX [#](/creator/twitter::1211086357/followers)  - X Week XXXXX +1.30% - X Month XXXXX +1.90% - X Months XXXXX +10% - X Year XXXXX +24% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1211086357/influencer_rank)  ### Social Influence [#](/creator/twitter::1211086357/influence) --- **Social category influence** [currencies](/list/currencies) XXXXX% [cryptocurrencies](/list/cryptocurrencies) XXXXX% [travel destinations](/list/travel-destinations) XXXX% **Social topic influence** [ctx](/topic/ctx) #6, [matterhorn](/topic/matterhorn) 5.56%, [coffin](/topic/coffin) XXXX% **Top accounts mentioned or mentioned by** [@myesmo](/creator/undefined) [@easledu](/creator/undefined) [@jcoasco](/creator/undefined) [@medwatchkate](/creator/undefined) [@dryukselurun](/creator/undefined) [@ilca](/creator/undefined) [@ilcanews](/creator/undefined) [@yjanjigianmd](/creator/undefined) [@neerajresearch](/creator/undefined) [@larvol](/creator/undefined) [@drangelalamarca](/creator/undefined) [@dianaroseroo](/creator/undefined) [@lorenzarimassa](/creator/undefined) [@basgrootkoerkam](/creator/undefined) [@michaelkuanchi1](/creator/undefined) [@renohemonc](/creator/undefined) ### Top Social Posts [#](/creator/twitter::1211086357/posts) --- Top posts by engagements in the last XX hours "PARERE trial: Panitumumab retreatment followed by regorafenib vs the reverse sequence in chemorefractory mCRC with RAS/ BRAF WT ctDNA #ESMO25 #ESMOAmbassadors 👉 mOS: XXXX vs 11.7mo 👉Better PFS for pani in both arms 🧐negative trial but rechallenge is an option in 4L @myesmo" [X Link](https://x.com/ArndtVogel/status/1979545038720753686) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T13:48Z 8829 followers, 4851 engagements "CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs XX mo 👉 DFS: XX vs XX mo 👉 MPR: XX vs X% 🧐Very promising results neoadjuvant strategies will be the future in HCC @myesmo @EASLedu @ilca" [X Link](https://x.com/ArndtVogel/status/1979850194520047944) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-19T10:00Z 8829 followers, 9619 engagements "TALENTop phs 3: Liver resection versus continued atezolizumab plus bevacizumab in locally advanced HCC after atezo/bev treatment #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs vs XX mo 🧐great study design: response adapted subsequent therapy. Multimodal therapy in HCC is key @myesmo @EASLedu @ILCAnews" [X Link](https://x.com/ArndtVogel/status/1980200970685481008) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:14Z 8829 followers, 3359 engagements "PRODIGE 81/FFCD 2101 - TRIPLET HCC: Adding IPI to ATEZO + BEV in 1L uHCC #ESMO25 #ESMOAmbassadors 👉ORR: XX vs XXXX% 👉mPFS: XXX vs XXX mo 👉mOS: CC vs XX mo 🧐No benefit for adding IPI surprisingly clear negative.not enough anti-CTL4 @myesmo" [X Link](https://x.com/ArndtVogel/status/1979479438774452412) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T09:27Z 8816 followers, 6157 engagements "IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II: Durvalumab plus tremelimumab in advanced BTC after failure of platinum-based CTx #ESMO25 #ESMOAmbassadors 👉 ICI is now SOC in 1L no convincing single for dual ICI in 2L but there are some ICI responder 👉we need biomarkers @myESMO" [X Link](https://x.com/ArndtVogel/status/1980202790564868298) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:21Z 8811 followers, 1996 engagements "MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: XX% MPR: XX% any: XX% 👉 OS: HR: 0.78; 36-mo OS: XX vs XX% 🧐OS improved independent of TAP better in responders new SOC @myesmo" [X Link](https://x.com/ArndtVogel/status/1979158577697747093) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-17T12:12Z 8829 followers, 15.5K engagements "PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: XX (-) vs XX% (+) 🧐Very innovative trail design ctDNA guided ACT is the future @myesmo" [X Link](https://x.com/ArndtVogel/status/1979531991625367833) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T12:56Z 8829 followers, 10.9K engagements "Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2 #ESMO25 #ESMOAmbassadors 👉 patient based comparison 👉 Final coffin nail for CTx 👉 Can we omit surgery next 🧐 Amazing efficacy for ICI in MSI CRC @myesmo" [X Link](https://x.com/ArndtVogel/status/1979536022305468468) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T13:12Z 8829 followers, 5208 engagements "HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D PDAC #ESMO25 #ESMOAmbassadors 👉 ORR: XX% DCR XX% 👉 6mo PFS rate: XX% 👉 manageable safety 🧐 KRASi are the future in 1L @myesmo" [X Link](https://x.com/ArndtVogel/status/1979954921983394196) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-19T16:56Z 8829 followers, 5242 engagements "Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: X vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC more trials to come. @myesmo" [X Link](https://x.com/ArndtVogel/status/1980204184827031608) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:27Z 8829 followers, 6096 engagements "CASSANDRA phs 3: short vs long-course pre-operative CTx for stage I-III PDAC #ESMO25 #ESMOAmbassadors 👉 No difference in EFS between short vs long pre-OP CTx 👉but high CA19.9 response N0 resection dose intensity 🧐the jury is still out for best neoadjuvant approach @myesmo" [X Link](https://x.com/ArndtVogel/status/1980206290300481756) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:35Z 8829 followers, 4334 engagements "🔥Presidential Session🔥 AGITG DYNAMIC-III trial : ctDNA-guided adjuvant CTx de-escalation in stage III CRC analysis of the ctDNA-cohort #ESMO25 #ESMOAmbassadors 👉 markedly reduced oxaliplatin exposure 👉 non-inferiority not shown specifically in high risk pts 👉 ctDNA burden prognostic 🧐feasible but not yet there.predictive uncertainty @myesmo" [X Link](https://x.com/ArndtVogel/status/1980291243868344735) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T15:13Z 8829 followers, 4318 engagements "🔥Presidential Session🔥 FORTITUDE-101 phase III: Bemarituzumab plus CTx for advanced FGFR2b+ G/GEJC #ESMO25 #ESMOAmbassadors 👉mOS:17.9 vs XXXX mo but less benefit w/ follow up 👉Ocular AEs may be a concern 🧐Positive trial but not practice changing 👏great discussion by @YJanjigianMD @myesmo" [X Link](https://x.com/ArndtVogel/status/1980306502188474585) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T16:13Z 8829 followers, 7207 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ArndtVogel Arndt Vogel
Arndt Vogel posts on X about ctx, matterhorn, coffin the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +1,821%
- X Month XXXXXX +280%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%
Mentions: XX #
- X Year XX -XXXX%
Followers: XXXXX #
- X Week XXXXX +1.30%
- X Month XXXXX +1.90%
- X Months XXXXX +10%
- X Year XXXXX +24%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence currencies XXXXX% cryptocurrencies XXXXX% travel destinations XXXX%
Social topic influence ctx #6, matterhorn 5.56%, coffin XXXX%
Top accounts mentioned or mentioned by @myesmo @easledu @jcoasco @medwatchkate @dryukselurun @ilca @ilcanews @yjanjigianmd @neerajresearch @larvol @drangelalamarca @dianaroseroo @lorenzarimassa @basgrootkoerkam @michaelkuanchi1 @renohemonc
Top Social Posts #
Top posts by engagements in the last XX hours
"PARERE trial: Panitumumab retreatment followed by regorafenib vs the reverse sequence in chemorefractory mCRC with RAS/ BRAF WT ctDNA #ESMO25 #ESMOAmbassadors 👉 mOS: XXXX vs 11.7mo 👉Better PFS for pani in both arms 🧐negative trial but rechallenge is an option in 4L @myesmo"
X Link @ArndtVogel 2025-10-18T13:48Z 8829 followers, 4851 engagements
"CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs XX mo 👉 DFS: XX vs XX mo 👉 MPR: XX vs X% 🧐Very promising results neoadjuvant strategies will be the future in HCC @myesmo @EASLedu @ilca"
X Link @ArndtVogel 2025-10-19T10:00Z 8829 followers, 9619 engagements
"TALENTop phs 3: Liver resection versus continued atezolizumab plus bevacizumab in locally advanced HCC after atezo/bev treatment #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs vs XX mo 🧐great study design: response adapted subsequent therapy. Multimodal therapy in HCC is key @myesmo @EASLedu @ILCAnews"
X Link @ArndtVogel 2025-10-20T09:14Z 8829 followers, 3359 engagements
"PRODIGE 81/FFCD 2101 - TRIPLET HCC: Adding IPI to ATEZO + BEV in 1L uHCC #ESMO25 #ESMOAmbassadors 👉ORR: XX vs XXXX% 👉mPFS: XXX vs XXX mo 👉mOS: CC vs XX mo 🧐No benefit for adding IPI surprisingly clear negative.not enough anti-CTL4 @myesmo"
X Link @ArndtVogel 2025-10-18T09:27Z 8816 followers, 6157 engagements
"IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II: Durvalumab plus tremelimumab in advanced BTC after failure of platinum-based CTx #ESMO25 #ESMOAmbassadors 👉 ICI is now SOC in 1L no convincing single for dual ICI in 2L but there are some ICI responder 👉we need biomarkers @myESMO"
X Link @ArndtVogel 2025-10-20T09:21Z 8811 followers, 1996 engagements
"MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: XX% MPR: XX% any: XX% 👉 OS: HR: 0.78; 36-mo OS: XX vs XX% 🧐OS improved independent of TAP better in responders new SOC @myesmo"
X Link @ArndtVogel 2025-10-17T12:12Z 8829 followers, 15.5K engagements
"PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: XX (-) vs XX% (+) 🧐Very innovative trail design ctDNA guided ACT is the future @myesmo"
X Link @ArndtVogel 2025-10-18T12:56Z 8829 followers, 10.9K engagements
"Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2 #ESMO25 #ESMOAmbassadors 👉 patient based comparison 👉 Final coffin nail for CTx 👉 Can we omit surgery next 🧐 Amazing efficacy for ICI in MSI CRC @myesmo"
X Link @ArndtVogel 2025-10-18T13:12Z 8829 followers, 5208 engagements
"HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D PDAC #ESMO25 #ESMOAmbassadors 👉 ORR: XX% DCR XX% 👉 6mo PFS rate: XX% 👉 manageable safety 🧐 KRASi are the future in 1L @myesmo"
X Link @ArndtVogel 2025-10-19T16:56Z 8829 followers, 5242 engagements
"Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: X vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC more trials to come. @myesmo"
X Link @ArndtVogel 2025-10-20T09:27Z 8829 followers, 6096 engagements
"CASSANDRA phs 3: short vs long-course pre-operative CTx for stage I-III PDAC #ESMO25 #ESMOAmbassadors 👉 No difference in EFS between short vs long pre-OP CTx 👉but high CA19.9 response N0 resection dose intensity 🧐the jury is still out for best neoadjuvant approach @myesmo"
X Link @ArndtVogel 2025-10-20T09:35Z 8829 followers, 4334 engagements
"🔥Presidential Session🔥 AGITG DYNAMIC-III trial : ctDNA-guided adjuvant CTx de-escalation in stage III CRC analysis of the ctDNA-cohort #ESMO25 #ESMOAmbassadors 👉 markedly reduced oxaliplatin exposure 👉 non-inferiority not shown specifically in high risk pts 👉 ctDNA burden prognostic 🧐feasible but not yet there.predictive uncertainty @myesmo"
X Link @ArndtVogel 2025-10-20T15:13Z 8829 followers, 4318 engagements
"🔥Presidential Session🔥 FORTITUDE-101 phase III: Bemarituzumab plus CTx for advanced FGFR2b+ G/GEJC #ESMO25 #ESMOAmbassadors 👉mOS:17.9 vs XXXX mo but less benefit w/ follow up 👉Ocular AEs may be a concern 🧐Positive trial but not practice changing 👏great discussion by @YJanjigianMD @myesmo"
X Link @ArndtVogel 2025-10-20T16:13Z 8829 followers, 7207 engagements